Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7436460 | 0.78 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1HSD17B10MAPT | |
| SCHEMBL4753186 | 0.78 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1HSD17B10MAPT | |
| SCHEMBL5033264 | 0.76 | TTR (0.52) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL22473980 | 0.75 | ALDH1A1 (0.65) | MEN1KMT2AALDH1A1HSD17B10MAPT | |
| SCHEMBL5114051 | 0.72 | CES1 (0.71) | ALDH1A1HSD17B10CES1BCHETGM2 | |
| SCHEMBL29649695 | 0.72 | CES1 (0.71) | ALDH1A1HSD17B10CES1BCHETGM2 | |
| SCHEMBL7558704 | 0.72 | CES1 (0.34) | MEN1KMT2AALDH1A1HSD17B10HTT | |
| SCHEMBL15571795 | 0.69 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1HSD17B10MAPT | |
| SCHEMBL10134043 | 0.69 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1HSD17B10MAPT | |
| SCHEMBL7564533 | 0.69 | CA12 (0.56) | MEN1KMT2AALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398254-A2 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | Memorial Sloan Kettering Cancer Center (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12023371-B2 | Terminally modified RNA | MODERNATX, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11981703-B2 | Polynucleotide constructs | SIRIUS THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-25 | — | — | US | disclosed |
| US-20240123035-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-18 | — | — | US | disclosed |
| EP-4351662-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| EP-2991655-B1 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3737673-B1 | PROCESS FOR PREPARING HALICHONDRIN MACROLIDES AND ANALOGS THEREOF BY A PRINS REACTION, AND INTERMEDIATES OF THIS PROCESS | EISAI R&D MAN CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2013130161-A1 | METHODS OF RESPONDING TO A BIOTHREAT | modeRNA Therapeutics (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013106432-A1 | BENZHYDROL-PYRAZOLE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-RX, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2013090186-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013090648-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | MEN1 2176/4885KMT2A 1675/4885ALDH1A1 2620/4885 |
| US-11981703-B2 | Polynucleotide constructs | PHAX, CPSF6, RNGTT | MEN1 4565/4885KMT2A 3891/4885ALDH1A1 3953/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | MEN1 1914/4885KMT2A 2306/4885ALDH1A1 2694/4885 |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | CEP170, PIN1, FKBP3 | MEN1 2531/4885KMT2A 4097/4885ALDH1A1 4800/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | MEN1 2749/4885KMT2A 973/4885ALDH1A1 1969/4885 |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | IGF2BP1, IGF2BP2, NSUN2 | MEN1 1697/4885KMT2A 2263/4885ALDH1A1 4727/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | MEN1 2203/4885KMT2A 3223/4885ALDH1A1 4488/4885 |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | PHAX, NSUN2, RNMT | MEN1 3299/4885KMT2A 2611/4885ALDH1A1 4792/4885 |
| US-12023371-B2 | Terminally modified RNA | RNGTT, NSUN3, RNMT | MEN1 2398/4885KMT2A 582/4885ALDH1A1 4235/4885 |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | TIA1, PAIP1, PHAX | MEN1 2259/4885KMT2A 3656/4885ALDH1A1 4819/4885 |
| US-20240123035-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | MEN1 2203/4885KMT2A 3223/4885ALDH1A1 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.